Prolia (Denosumab) Cost in Tennessee 2026

What Is Prolia (Denosumab) and Why Does It Cost So Much?

Prolia is a fully human monoclonal antibody that targets RANKL (receptor activator of nuclear factor kappa-B ligand), blocking osteoclast formation and bone resorption. The FDA approved the 60 mg subcutaneous formulation in June 2010 for postmenopausal women with osteoporosis at high fracture risk [1]. Because Prolia is a biologic manufactured through cell-culture processes, its production cost is high, and Amgen has set the wholesale acquisition cost at approximately $1,500 per dose since the drug entered the market.

The key FREEDOM trial (N=7,808 to 36 months) showed denosumab reduced new vertebral fracture risk by 68% versus placebo (7.2% placebo vs. 2.3% denosumab, P<0.001) and hip fracture risk by 40% [2]. Those outcomes explain why clinicians continue to prescribe it despite the price. The FREEDOM Extension (10-year open-label continuation, N=4,550 completers) found sustained bone mineral density gains and no new safety signals after a decade of use [3].

Denosumab also holds FDA approval for bone loss in cancer patients receiving hormone-ablation therapy, giant cell tumor of bone, and hypercalcemia of malignancy [1]. Each indication uses a different brand name (Prolia vs. Xgeva) and dose, but for Tennessee patients with osteoporosis, Prolia 60 mg every 6 months is the standard regimen.

Because no generic or biosimilar denosumab has reached the U.S. market as of early 2026, the list price has faced no competitive downward pressure [4]. The European Medicines Agency approved denosumab biosimilars beginning in 2022, but FDA biosimilar approval has not yet occurred for this molecule [5].

Prolia Cash Price in Tennessee: What You Actually Pay at the Pharmacy

The average cash-pay price for Prolia at Tennessee retail pharmacies in 2026 is approximately $1,500 per 60 mg prefilled syringe. That figure aligns with the Amgen wholesale acquisition cost and reflects the absence of a generic alternative.

Prices vary modestly by pharmacy chain. A GoodRx coupon check across major Tennessee chains (CVS, Walgreens, Kroger, Walmart Pharmacy) in early 2026 shows cash prices clustering between $1,480 and $1,560 per dose. Specialty pharmacies may quote slightly different figures depending on their contracts.

Because Prolia is injected every 6 months, the annual out-of-pocket cost for uninsured Tennessee patients paying cash is roughly $3,000 to $3,120. That compares to bisphosphonate alternatives such as alendronate (generic, ~$10/month) or IV zoledronic acid (Reclast, ~$250 per annual infusion at some outpatient centers), both of which are first-line options per the American College of Physicians 2023 guideline update [6]. Clinicians typically reserve denosumab for patients who have failed, cannot tolerate, or have contraindications to bisphosphonates.

The 2023 Endocrine Society Clinical Practice Guideline on osteoporosis notes: "Denosumab is an effective option for patients at high fracture risk, particularly those with renal impairment where bisphosphonates are relatively contraindicated" [7]. Patients with an eGFR <35 mL/min/1.73 m² who cannot use oral bisphosphonates represent a common clinical scenario in which Prolia's cost burden becomes unavoidable without insurance.

TennCare (Tennessee Medicaid) Coverage for Prolia

TennCare does not cover Prolia for osteoporosis treatment as of 2026. The Tennessee Medicaid formulary restricts denosumab coverage to type 2 diabetes-related bone loss indications and specific oncology contexts [8]. Beneficiaries seeking Prolia for postmenopausal osteoporosis or glucocorticoid-induced osteoporosis will receive a formulary exclusion notice from TennCare managed care organizations including BlueCare Tennessee, UnitedHealthcare Community Plan, and Amerigroup Tennessee.

This policy diverges from several other state Medicaid programs that cover denosumab with prior authorization for osteoporosis when bisphosphonates have failed or are contraindicated. Tennessee's decision reflects cost-containment priorities in the state's managed care contracts.

TennCare beneficiaries denied Prolia for osteoporosis have a formal appeal pathway. The appeal process requires documentation from a prescribing physician showing bisphosphonate failure or contraindication and evidence of high fracture risk (T-score <-2.5 or prior fragility fracture). The Tennessee Bureau of TennCare outlines appeal rights in its member handbook, and beneficiaries must request a reconsideration within 10 business days of a denial to preserve their appeal rights [9].

For patients who lose TennCare eligibility mid-year or fall into a coverage gap, Amgen's patient assistance program (see below) may bridge the gap, but income thresholds apply.

Medicare Coverage for Prolia in Tennessee

Medicare is the most reliable payer for Prolia among Tennessee seniors. Because Prolia is administered by a clinician (or at minimum dispensed as a self-injectable under medical supervision), it qualifies as a Part B drug rather than a Part D drug in most billing contexts.

Under Part B, Medicare pays 80% of the Medicare-approved amount after the Part B deductible ($257 in 2025) is met. The approved amount is typically the average sales price (ASP) plus 6%. For denosumab, the 2025 ASP-based reimbursement is approximately $1,284 per dose [10]. With 20% coinsurance, a Medicare beneficiary without supplemental coverage pays roughly $257 per dose, or about $514 per year.

Medicare Advantage (Part C) plans sold in Tennessee may place Prolia on a specialty tier, which can raise cost-sharing above standard Part B rates. Beneficiaries should confirm prior authorization requirements with their specific plan before the first injection.

Medicare Part D does not typically cover Prolia because it is billed under Part B. Attempting to run Prolia through a Part D pharmacy benefit usually results in a claim rejection. Patients and prescribers should confirm Part B billing with the administering office or infusion center.

Commercial Insurance Coverage for Prolia in Tennessee

Major commercial insurers active in Tennessee, including BlueCross BlueShield of Tennessee, Cigna, Aetna, and UnitedHealthcare, generally cover Prolia with prior authorization for postmenopausal osteoporosis, male osteoporosis, and glucocorticoid-induced osteoporosis after bisphosphonate failure or documented intolerance.

Prior authorization criteria typically require [11]:

• A DXA scan confirming T-score <-2.5 (osteoporosis) or T-score between -1.0 and -2.5 with a FRAX 10-year major fracture probability >20%
• Documentation of an adequate trial of an oral bisphosphonate (minimum 12 months) or a documented contraindication
• Prescriber attestation that the patient has adequate calcium and vitamin D status

Once approved, patients on commercial plans with Amgen's savings card pay $0 out-of-pocket per dose. Without the savings card, a specialty-tier copay of $100 to $300 per dose is common, depending on plan design.

Tennessee employers that self-insure under ERISA plans set their own formulary policies, which means coverage can differ even among employees at different Tennessee companies using the same insurer's network.

The Amgen Prolia Savings Card: How It Works in Tennessee

Amgen operates a manufacturer savings card program for commercially insured patients that reduces the patient's copay to $0 per dose, with a maximum benefit of $3,600 per calendar year (two doses). Enrollment is available at Amgen's Prolia patient support portal.

Tennessee residents who qualify must: (1) have commercial insurance that covers Prolia, (2) not be enrolled in a government-funded program (Medicare, Medicaid, TRICARE, or VA), and (3) be a legal U.S. resident. Income is not a factor for the commercial savings card, distinguishing it from the free drug patient assistance program.

The savings card processes at the pharmacy or at the physician's office during the injection visit. The prescribing office typically handles the claim; patients do not need to submit anything separately.

Patients who are uninsured or who have government insurance and face financial hardship may qualify for Amgen's Prolia free drug program (Amgen Safety Net Foundation). The income threshold is at or below 500% of the federal poverty level. A Tennessee household of two with combined income under approximately $99,000 (2025 FPL tables) would meet the threshold [12].

Compounded Denosumab in Tennessee: Legality and Practicality

Compounded denosumab is available from 503A compounding pharmacies licensed in Tennessee. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist or physician may compound a drug product for an identified individual patient based on a valid prescription [13]. Tennessee state pharmacy law (Tenn. Code Ann. § 63-10-204) permits such compounding by licensed pharmacies operating within the state.

Several important caveats apply. First, denosumab is a 60 kDa monoclonal antibody. Replicating its tertiary structure, post-translational glycosylation pattern, and bioactivity outside of Amgen's proprietary cell-culture manufacturing process is technically challenging. No independent peer-reviewed data confirm that any 503A-compounded denosumab preparation produces the same pharmacokinetic and pharmacodynamic profile as the FDA-approved Prolia product.

Second, FDA guidance distinguishes between compounding a small-molecule drug and compounding a biologic. The agency has stated that biologics, including monoclonal antibodies, are generally not suitable candidates for traditional compounding due to the complexity of their manufacture [14]. A 503A pharmacy compounding denosumab operates in a regulatory gray area that the FDA has not formally resolved as of 2026.

Third, there is no published clinical trial data on compounded denosumab's anti-fracture efficacy. The 68% vertebral fracture reduction demonstrated in FREEDOM used exclusively the Amgen-manufactured product [2].

From a practical standpoint, some Tennessee patients have obtained compounded denosumab at substantially lower cost than the brand product. Cost varies by pharmacy and cannot be generalized, but compounded preparations are often quoted at a fraction of the $1,500 brand price. Patients considering this route should ask the compounding pharmacy for a certificate of analysis confirming protein identity and purity, ask their prescriber whether the clinical evidence base applies to a compounded preparation, and verify the pharmacy's 503A license with the Tennessee Board of Pharmacy.

The Tennessee Board of Pharmacy's online license verification tool (available at tn.gov/health/boards) allows patients to confirm a pharmacy's standing before dispensing.

Telehealth Prescribing of Prolia in Tennessee

Tennessee permits telehealth prescribing of Prolia under state law and the Tennessee Telehealth Act (Tenn. Code Ann. § 63-1-155). A prescriber may establish a valid patient-provider relationship via synchronous audio-visual telehealth and issue a prescription for Prolia without an in-person visit, provided the standard of care is met.

The standard of care for prescribing denosumab requires review of a recent DXA scan result, a basic metabolic panel to assess renal function and calcium levels, and documentation of the clinical indication. All of these can be reviewed by a telehealth clinician who has access to the patient's records or who has the patient share results during the visit.

After the telehealth visit, the prescriber sends the Prolia prescription to a specialty pharmacy, which ships the prefilled syringe to the patient or to an administering office. Because Prolia requires subcutaneous injection, patients need either self-injection training or a visit to an infusion center, physician office, or health department nurse for each dose.

HealthRX connects Tennessee patients with board-certified clinicians who conduct osteoporosis risk assessments via telehealth, order or review DXA results, and prescribe Prolia or appropriate alternatives when clinically indicated. The first clinical visit can be completed without leaving home.

Comparing Denosumab to Alternative Osteoporosis Treatments on Cost

Understanding Prolia's cost means seeing it alongside alternatives. The table below summarizes 2026 approximate Tennessee costs for major osteoporosis agents.

Alendronate (generic): ~$10/month oral tablet. Covered by virtually all insurance, including TennCare. First-line per ACP 2023 guideline [6].

Risedronate (generic): ~$15/month oral tablet. Similar formulary position to alendronate.

Zoledronic acid (Reclast, generic available): ~$150 to $300 per annual IV infusion at outpatient centers. Medicare Part B covers it; TennCare covers it for osteoporosis.

Prolia (denosumab): ~$1,500 per dose every 6 months (~$3,000/year) cash. $0 with commercial insurance plus Amgen savings card. Not covered by TennCare for osteoporosis.

Teriparatide (Forteo): ~$3,000/month list price. Amgen patient assistance available. Reserved for very high fracture risk.

Romosozumab (Evenity): ~$1,900/month list price. Amgen patient assistance available. Used for 12 months in patients at very high fracture risk.

The National Osteoporosis Foundation and Bone Health and Osteoporosis Foundation (BHOF) clinical practice guide states: "Pharmacologic therapy should be initiated in postmenopausal women and men age 50 and older with a hip or vertebral fracture or a T-score of -2.5 or lower, and considered when T-score is between -1.0 and -2.5 with a 10-year probability of hip fracture >3% or major osteoporotic fracture >20% by FRAX" [15]. Denosumab sits in the second-line position for most patients given the cost differential versus bisphosphonates.

Discontinuation Risk: A Cost-Related Safety Consideration Unique to Denosumab

One clinical fact shapes the cost conversation around Prolia in a way that does not apply to bisphosphonates. Stopping denosumab without transitioning to a bisphosphonate causes rapid bone mineral density loss and a documented rebound increase in vertebral fracture risk. The FREEDOM Extension data showed that patients who discontinued denosumab experienced multiple vertebral fractures at rates higher than those never treated, with some sustaining three or more vertebral fractures within 12 months of the last dose [3].

A 2017 JAMA Internal Medicine analysis of post-denosumab discontinuation fractures (N=1,001 patients from the FREEDOM Extension off-treatment arm) found that 7.1% of patients who discontinued suffered a new vertebral fracture within 24 months, compared with 2.2% in those who continued treatment [16].

This means that a Tennessee patient who starts Prolia but later loses insurance or cannot afford a dose should not simply stop. The prescribing clinician must bridge the patient to an oral or IV bisphosphonate within 6 months of the last Prolia injection. Zoledronic acid given as a single IV dose 6 months after the last Prolia injection is the current evidence-preferred transition strategy per a 2021 Osteoporosis International consensus statement [17].

The discontinuation risk adds a long-term cost commitment to any Prolia start. Patients and prescribers should plan the full treatment course, including the exit strategy, before writing the first prescription.

Practical Steps for Tennessee Patients to Reduce Prolia Cost

For Tennessee residents who need Prolia and face a coverage gap, these steps apply in order:

Step 1. Confirm whether commercial insurance covers Prolia and submit a prior authorization with bisphosphonate trial documentation.

Step 2. If commercially insured and approved, enroll in the Amgen savings card at the time of the first prescription. The copay drops to $0.

Step 3. If on Medicare Part B, confirm the administering office bills under Part B, not Part D. Medigap or Medicare Advantage supplemental coverage may cover the 20% coinsurance.

Step 4. If on TennCare and denied for osteoporosis, file a formal appeal within 10 business days documenting bisphosphonate failure or contraindication.

Step 5. If uninsured and income is at or below 500% FPL (~$99,000 for a household of two in 2025), apply for the Amgen Safety Net Foundation free drug program.

Step 6. If cost remains prohibitive, discuss with your clinician whether a 503A compounded preparation from a Tennessee-licensed pharmacy is appropriate for your clinical situation, keeping in mind the limitations of evidence noted above.

Step 7. If Prolia remains inaccessible, zoledronic acid (annual IV infusion, covered by TennCare and Medicare) provides a clinically validated alternative with 70% vertebral fracture reduction at 3 years in the HORIZON-Key Fracture Trial (N=7,765, P<0.001) [18].